Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Parsabiv Approved With Unusual Postmarketing Requirements

Executive Summary

US FDA obliges hypothesis-testing observational study to determine whether there is an association with gastrointestinal bleeding and the drug; postmarketing requirements usually seek to determine frequency between a drug and adverse events known to be associated.

Advertisement

Related Content

Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market
Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108
Amgen's Parsabiv's Gets EU Approval While It Languishes At The FDA
Amgen's Parsabiv's EU Approval Contrasts With US FDA Rejection
Amgen's Reticence On Parsabiv Complete Response Letter Revives Transparency Issue
Amgen Gets Parsabiv CRL, Gives No Clues As To Why

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120030

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel